跳转至内容
Merck
CN

P4394

顺铂

≥99.99% (trace metal analysis), crystalline, macrophage activator

别名:

顺-二氯二氨基铂(II), 顺式-二胺二氯铂, 顺氯氨铂

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
Pt(NH3)2Cl2
化学文摘社编号:
分子量:
300.05
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
239-733-8
MDL number:
Form:
crystalline
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

顺铂, crystalline

form

crystalline

Quality Level

color

yellow

mp

270 °C (lit.)

antibiotic activity spectrum

neoplastics

mode of action

DNA synthesis | interferes

originator

Corden

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Application

顺-二氨基铂(II)二氯化物已用于:
  • 耳蜗外植体细胞的活力测量
  • 抑制卵巢癌细胞系中的细胞增殖和化学敏感性
  • 口服鳞状细胞癌中MTT [3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化物]细胞活力检测

Biochem/physiol Actions

强效的铂基抗肿瘤剂。与 DNA 二核苷酸 d(pGpG) 形成细胞毒性加合物,诱导链内交联。
有效的化学免疫治疗药物; 通过激活巨噬细胞和免疫系统的其他细胞来刺激免疫反应。顺铂处理的巨噬细胞在体外显示出增强的抗原呈递功能。治疗增加了巨噬细胞中NF-κB的含量和易位。顺铂的作用受激酶、磷酸酶和Ca2+/钙调蛋白的调节。与DNA二核苷酸d(pGpG)形成细胞毒性加合物,诱导链内交联。

Features and Benefits

该化合物在受体分类和信号转导手册的 半胱天冬酶 页面上有详细描述。如需浏览其他手册页面,请点击此处
该化合物是细胞凋亡研究的特色产品。点击此处以了解更多的细胞凋亡特色产品。可访问sigma.com/discover-bsm了解更多关于用于其他研究领域生物活性小分子。
该化合物由Corden开发。如需浏览其他药物开发的化合物和批准的药物/候选药物清单,请单击此处

Preparation Note

本品室温保存。密封保存于通风良好处。干燥。详见安全数据说明书(Safety Data Sheet)。

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

target_organs

Respiratory system

存储类别

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Hazard Classifications

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Calpain system protein expression and activity in ovarian cancer
Zhang S, et al.
Journal of Cancer Research and Clinical Oncology, 1-17 (2018)
Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance
Alam M, et al.
Head & Neck (2018)
Yi-Long Wu et al.
The Lancet. Oncology, 14(8), 777-786 (2013-06-21)
The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.
Lin Hou et al.
Life sciences, 232, 116561-116561 (2019-06-28)
The poor prognosis of ovarian cancer is mainly caused by chemotherapy resistance. Studies show that the Bcl-2 inhibitor ABT737 can significantly improve the effect of cisplatin and induce mitochondrial pathway apoptosis. However, the mechanism of ABT737 increases sensitivity to cisplatin
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring

商品

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

全球贸易项目编号

货号GTIN
P4394-100MG04061835558339
P4394-1G04061834374503
P4394-250MG04061834374510
P4394-25MG04061834374527

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持